Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on enzymatic, non-surgical therapies for tissue repair, and its news flow reflects this specialization. Company announcements frequently highlight clinical progress for its late-stage investigational product EscharEx®, including updates on the global VALUE Phase III trial in venous leg ulcers and planned studies in diabetic foot ulcers and pressure ulcers. Investors and healthcare professionals can follow how these trials evolve, along with peer-reviewed publications that analyze wound bed preparation and healing outcomes.
News about MediWound also covers the commercial and clinical use of its FDA-approved biologic NexoBrid®, indicated for enzymatic removal of eschar in thermal burns. Recent releases have described new clinical data on NexoBrid in traumatic tattoos from abrasion and blast injuries, as well as its role in scientific presentations at major burn congresses. Regulatory milestones, such as marketing approval in Australia and expansion to 45 countries, feature prominently in the company’s updates.
Operational and financial developments are another key theme in MDWD news. MediWound reports on expansion and commissioning of its GMP manufacturing facility in Yavne, Israel, designed to increase NexoBrid production capacity, and on BARDA- and U.S. Department of Defense-funded projects, including work on a room temperature-stable formulation. Quarterly and annual financial results, equity financings under shelf registration statements, and revenue guidance are detailed in regular press releases and associated conference calls.
For readers tracking MDWD, this news stream offers insight into clinical trial milestones, regulatory decisions, manufacturing readiness, government-supported programs, and financial performance. Bookmark this page to follow ongoing developments that shape MediWound’s burn and chronic wound therapy portfolio.
MediWound Ltd. (Nasdaq: MDWD) announced the upcoming release of its third-quarter financial results for the period ending September 30, 2020, scheduled for November 10, 2020, at 7:00 am ET. Following the announcement, a conference call will be held at 8:30 am ET to discuss the results. MediWound specializes in innovative therapies for severe burn and wound management, with notable products like NexoBrid and EscharEx, both leveraging patented proteolytic enzyme technology. NexoBrid has received marketing authorization in several countries, underscoring the company's regulatory progress.
MediWound Ltd. has completed enrollment for its Phase 3 pediatric clinical study of NexoBrid, aimed at treating severe burns in children. Following FDA's approval for expanded access to pediatric patients, the study involves 145 participants and will compare NexoBrid against standard care over a 12 and 24-month follow-up. Top-line results are expected in the second half of 2021. Funded by BARDA, the trial addresses significant challenges faced in pediatric burn management, potentially expanding NexoBrid's applications.
MediWound Ltd. (Nasdaq: MDWD) is investigating the effects of EscharEx on biofilm burden in chronic wounds, focusing on its potential to improve wound healing. Biofilms are linked to delayed healing and infections in 60%-100% of chronic wounds. Conventional treatment can be painful and costly, leading to interest in enzymatic debridement as a less invasive alternative. Preclinical studies suggest enzymes, including bromelain, could effectively disrupt biofilms. MediWound intends to conduct pharmacological studies to evaluate EscharEx's potential benefits on biofilms in chronic wounds.
MediWound Ltd. (NASDAQ: MDWD) announced that the FDA accepted its Biologics License Application (BLA) for NexoBrid® for eschar removal in patients with deep partial and full-thickness thermal burns. The FDA has set a PDUFA date of June 29, 2021, with no advisory committee meeting planned. The submission includes data from the pivotal Phase 3 DETECT trial that met its primary and secondary endpoints. NexoBrid is already approved in the EU and designated as an orphan biologic drug in multiple regions. Vericel Corporation holds exclusive North American rights, and BARDA supports the development.
MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company specializing in wound management, announced investor presentations in September 2020. CEO Sharon Malka will present at three virtual conferences: the Wells Fargo Virtual Healthcare Conference on September 10, H.C. Wainwright Annual Global Investment Conference on September 14, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21. MediWound is known for its innovative products, including NexoBrid and EscharEx, targeting severe burns and hard-to-heal wounds.
MediWound Ltd. (NASDAQ: MDWD) and its partner Vericel Corporation (NASDAQ: VCEL) announced that BARDA has accepted a $16.5 million shipment of NexoBrid, intended for public health emergency preparedness. This procurement includes additional deliveries through 2021, with an option for up to $50 million. The collaboration aims to ensure supply and training for treating severe burn injuries amid COVID-19. MediWound also submitted a Biologics License Application to the FDA for NexoBrid, which has been effective in clinical studies as a non-surgical solution for burn tissue removal.
MediWound Ltd. (NASDAQ: MDWD) announced the submission of a Biologics License Application (BLA) to the FDA for its product NexoBrid, designed for eschar removal in adults with deep partial-thickness and full-thickness thermal burns. The submission includes data from the successful Phase 3 DETECT study, which demonstrated safety and efficacy. NexoBrid is already approved in the EU and other regions and is supported by BARDA with a commitment of $16.5 million for procurement. This milestone could significantly benefit severe burn victims and public health preparedness in the U.S.
MediWound Ltd. (Nasdaq: MDWD) reported its Q1 2020 financial results with total revenues of $4.4 million, a significant increase from $0.5 million in Q1 2019. The operating loss narrowed to $2.2 million from $3.6 million year-over-year. Operating cash flow was $2.1 million, and the company held $27.3 million in cash and short-term investments, carrying no debt. MediWound resumed clinical trials for EscharEx treatment and expanded its contract with BARDA for NexoBrid, reflecting ongoing operational stability amidst the COVID-19 pandemic.
MediWound Ltd. (Nasdaq: MDWD) will release its financial results for Q1 2020 on May 20, 2020, at 7:00 am ET. Following this, a conference call will be held at 8:30 am ET to discuss the results. Participants can join via toll-free numbers or through the provided webcast link. MediWound focuses on developing innovative therapies for severe burns and hard-to-heal wounds. Its renowned products include NexoBrid and EscharEx, utilizing patented proteolytic enzyme technology.
Summary not available.